iflexis.be

What It Is

MONA is a medical AI tool/software project from Belgium, focused on health monitoring and early disease screening through retinal imaging. Its website emphasizes that retinal screening can be incorporated into routine health checkups to help identify eye diseases such as diabetic retinopathy, glaucoma, and age-related macular degeneration at an early stage, as well as assess how risk factors like diabetes, smoking, obesity, high cholesterol, high blood pressure, and lack of exercise affect population health.

Core Capabilities and Use Cases

Its main products include MONA DR and MONA GLC. MONA DR is designed for diabetic retinopathy screening; according to the website, it uses AI to quickly and accurately predict diabetic retinopathy. MONA GLC is intended for glaucoma screening, but is currently described as “under development.” Technically, MONA uses machine learning for retinal image analysis and combines retinal scans with personal data to identify biomarkers and characterize disease trajectories. Supported imaging sources include fundus photography and optical coherence tomography.

Pricing, Integration, and Privacy

The official website does not disclose its pricing model, free trial availability, procurement process, or payment methods. It also does not state whether it offers an API, hospital information system integration, or cloud/on-premise deployment options. On data privacy, the site clearly mentions that retinal scans and personal data are combined for analysis, but it does not provide further details on data encryption, de-identification, patient authorization, compliance frameworks, or data processing agreements—all of which are critical for healthcare procurement assessments.

Pros, Cons, and Limitations

MONA’s strengths are its focused direction and clearly defined clinical scenarios, making it relevant for diabetes management, primary-care eye screening, and population health programs. The team has backgrounds in biomedicine, life sciences, machine learning, and health IT, and MONA is a spin-off from the VITO Health Unit, giving it a research-based origin. The main drawback is that the publicly available materials are more conceptual than evidentiary, with limited information on model architecture, sample size, sensitivity/specificity, clinical validation, regulatory certification, or output examples. MONA GLC also does not yet appear to be a mature product.

Who It’s For and Access from China

MONA is better suited for healthcare institutions, public health programs, diabetes care systems, ophthalmology screening providers, or research partners seeking further evaluation and collaboration. Its accessibility from China cannot be determined from the website text; network connectivity, medical compliance, cross-border data handling, and payment support would all need to be confirmed separately. If deployed in China, local medical device regulation, data export requirements, and domestic retinal AI alternatives would also need to be considered.